| Lung Cancer |
1 |
1 |
| Biologic Therapy |
0 |
0.95 |
| Immunotherapy |
0 |
0.99 |
| Toxicology |
0 |
0.73 |
| Non-Small Cell Lung Cancer |
0 |
0.98 |
| Skin Cancer |
0 |
0.4 |
| Cancer |
0 |
0.39 |
| Small Cell Lung Cancer |
0 |
0.34 |
| Colon Cancer |
0 |
0.31 |
| Colorectal Cancer |
0 |
0.27 |
| Lung |
0 |
0.15 |
| Quality of Life |
0 |
0.15 |
| Melanoma |
0 |
0.13 |
| Adjuvant Chemotherapy |
0 |
0.1 |
| Chemotherapy |
0 |
0.1 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.07 |
| HIV Infection |
0 |
0.07 |
| Patient Safety |
0 |
0.06 |
| Adverse Effects |
0 |
0.05 |
| Biomarker |
0 |
0.05 |
| California |
0 |
0.05 |
| Canada |
0 |
0.05 |
| Food and Drug Administration (FDA) |
0 |
0.05 |
| Grant |
0 |
0.05 |
| Hospital |
0 |
0.05 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.05 |
| Pedal |
0 |
0.05 |
| Stress |
0 |
0.05 |
| Tumor |
0 |
0.05 |